4/20
04:20 pm
nktr
Nektar Therapeutics: 'Strong Buy' On REZPEG POC Established In AD/AA And Late-Stage Development [Seeking Alpha]
Low
Report
Nektar Therapeutics: 'Strong Buy' On REZPEG POC Established In AD/AA And Late-Stage Development [Seeking Alpha]
4/20
04:18 pm
nktr
Nektar Therapeutics Announces Proposed Public Offering [TheStreet.com]
Low
Report
Nektar Therapeutics Announces Proposed Public Offering [TheStreet.com]
4/20
04:01 pm
nktr
Nektar Therapeutics Announces Proposed Public Offering
Medium
Report
Nektar Therapeutics Announces Proposed Public Offering
4/20
04:00 pm
nktr
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Misleading Institutional Shareholders: Levi & Korsinsky
Low
Report
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Misleading Institutional Shareholders: Levi & Korsinsky
4/20
01:43 pm
nktr
Nektar Therapeutics (NKTR) Discusses 52-Week Topline Results From REZOLVE-AA Phase 2b Extension in Severe Alopecia Areata Transcript [Seeking Alpha]
Medium
Report
Nektar Therapeutics (NKTR) Discusses 52-Week Topline Results From REZOLVE-AA Phase 2b Extension in Severe Alopecia Areata Transcript [Seeking Alpha]
4/20
10:56 am
nktr
Nektar Therapeutics (NKTR) had its price target raised by HC Wainwright from $165.00 to $185.00. They now have a "buy" rating on the stock.
Medium
Report
Nektar Therapeutics (NKTR) had its price target raised by HC Wainwright from $165.00 to $185.00. They now have a "buy" rating on the stock.
4/20
10:56 am
nktr
Nektar Therapeutics (NKTR) had its price target raised by BTIG Research from $151.00 to $178.00. They now have a "buy" rating on the stock.
Medium
Report
Nektar Therapeutics (NKTR) had its price target raised by BTIG Research from $151.00 to $178.00. They now have a "buy" rating on the stock.
4/20
10:17 am
nktr
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
Low
Report
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
4/20
09:27 am
nktr
52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin [Yahoo! Finance]
Low
Report
52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin [Yahoo! Finance]
4/20
07:48 am
nktr
52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin [TheStreet.com]
High
Report
52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin [TheStreet.com]
4/20
07:30 am
nktr
52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin
High
Report
52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin
4/20
01:58 am
nktr
Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTR
High
Report
Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTR
4/19
12:18 pm
nktr
Nektar to Hold Conference Call to Discuss 52-Week Topline Results from the 16-Week Extension Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on April 20, 2026 [TheStreet.com]
High
Report
Nektar to Hold Conference Call to Discuss 52-Week Topline Results from the 16-Week Extension Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on April 20, 2026 [TheStreet.com]
4/19
12:00 pm
nktr
Nektar to Hold Conference Call to Discuss 52-Week Topline Results from the 16-Week Extension Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on April 20, 2026
High
Report
Nektar to Hold Conference Call to Discuss 52-Week Topline Results from the 16-Week Extension Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on April 20, 2026
4/18
09:52 pm
nktr
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTR
High
Report
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTR
4/17
12:00 pm
nktr
Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor Harm
Low
Report
Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor Harm
4/17
11:43 am
nktr
Bright Outlook for Nektar Therapeutics (NKTR) Hinges on Positive Trial Results [Yahoo! Finance]
Low
Report
Bright Outlook for Nektar Therapeutics (NKTR) Hinges on Positive Trial Results [Yahoo! Finance]
4/17
09:00 am
nktr
NKTR Shareholder Alert: Nektar Therapeutics Securities Class Action Lawsuit Investors With Losses May Join — The Gross Law Firm
Low
Report
NKTR Shareholder Alert: Nektar Therapeutics Securities Class Action Lawsuit Investors With Losses May Join — The Gross Law Firm
4/16
10:30 am
nktr
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
Medium
Report
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
4/16
10:00 am
nktr
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers - NKTR
Medium
Report
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers - NKTR
4/16
09:56 am
nktr
NKTR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026
Medium
Report
NKTR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026
4/16
09:00 am
nktr
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Hiding Enrollment Protocol Failures: SueWallSt
Low
Report
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Hiding Enrollment Protocol Failures: SueWallSt
4/16
01:00 am
nktr
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit
Low
Report
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit
4/15
11:02 pm
nktr
ROSEN, A LEADING NATIONAL FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTR
Low
Report
ROSEN, A LEADING NATIONAL FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTR
4/15
03:20 pm
nktr
Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Low
Report
Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit